Leerink Partners Cuts Abbott Laboratories (NYSE:ABT) Price Target to $106.00

24 Apr 2026, 01:44 by Renee Jackson · The Cerbat Gem

Abbott Laboratories (NYSE:ABT – Free Report) had its target price reduced by Leerink Partners from $119.00 to $106.00 in a research report sent to investors on Tuesday morning,MarketScreener reports. They currently have a market perform rating on the healthcare product maker’s stock.

A number of other brokerages have also recently commented on ABT. Benchmark dropped their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. JPMorgan Chase & Co. dropped their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. BTIG Research restated a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a report on Friday, April 17th. Mizuho dropped their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Finally, Citigroup dropped their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Check Out Our Latest Analysis on Abbott Laboratories

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $92.45 on Tuesday. The stock has a market cap of $161.02 billion, a price-to-earnings ratio of 25.90, a price-to-earnings-growth ratio of 1.53 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The stock has a 50 day moving average price of $106.39 and a 200-day moving average price of $117.64. Abbott Laboratories has a one year low of $90.72 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.49 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. 0.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of ABT. Brighton Jones LLC raised its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its position in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank raised its position in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC raised its position in shares of Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Large-market tailwind: a new IoT medical‑devices market report forecasts strong secular growth for connected and remote-monitoring devices through 2036, supporting Abbott’s device franchises (long-term demand upside). IoT Medical Devices Market Research and Global Forecast Report 2026-2036
Positive Sentiment: “Most oversold” commentary: coverage noting Abbott as one of the most oversold healthcare names may prompt value-oriented buying and short-covering, supporting near-term rebounds. Abbott is the most oversold healthcare stock as Q1 earnings roll on
Neutral Sentiment: Elevated investor attention: Zacks and Yahoo note heavy search/interest in ABT, which can increase volatility and trading volume but doesn’t directly change fundamentals. Investors Heavily Search Abbott Laboratories (ABT)
Neutral Sentiment: Competitive/industry note: unrelated coverage of Intuitive Surgical’s platform refresh highlights competitive dynamics in surgical robotics/devices — worth watching for competitive impact but not an immediate Abbott-specific catalyst. How ISRG Just Secured The U.S. Market
Negative Sentiment: UBS trims price target to $135 — a reduction in analyst optimism that can cap upside and weigh on investor sentiment despite the company’s solid Q1. UBS Group Cuts Abbott Laboratories (NYSE:ABT) Price Target to $135.00
Negative Sentiment: Argus issues a pessimistic forecast for ABT — adds to negative analyst noise and could pressure the stock if other firms follow suit. Argus Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price
Negative Sentiment: Daiwa downgrades ABT to neutral and sets a $92 target — implies limited near-term upside and may influence short‑term seller behavior. Finviz (Daiwa downgrade note)
Negative Sentiment: Barclays lowers expectations for ABT — another bearish signal from the sell side that contributes to downward pressure on sentiment and potential re-rating risk. Barclays Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.